Steven Leonard Chapman, serving as both Chief Executive Officer and President of Natera, Inc., executed a substantial sale of company equity on June 4, 2026. According to the filing, Mr. Chapman disposed of 43,124 shares of Natera common stock during this transaction. The aggregate value of these sales reached approximately $9.09 million. The execution of these shares occurred at prices fluctuating between $212.4187 and $226.9699 per share. The reported pricing for these transactions reflects weighted average figures, as the divestment was completed through multiple trades within the specified price range.
The transaction was conducted under the framework of a Rule 10b5-1 trading plan. Mr. Chapman originally adopted this automated trading arrangement on December 11, 2023. The plan was subsequently amended on two occasions: first on December 2, 2024, and most recently on March 5, 2026. Following the completion of this latest sale, Mr. Chapman's direct ownership of Natera common stock stands at 108,743 shares. The utilization of a pre-arranged trading plan indicates that the sale was scheduled in advance according to set parameters rather than being driven by immediate market timing decisions by the executive.
This insider activity occurs against a specific market backdrop for Natera. The company's stock has generated a 31% return over the trailing twelve-month period. Despite this longer-term performance, the stock currently trades at $215.31, reflecting a 3.6% decline over the past week. Market analysis from InvestingPro suggests that the current valuation levels may indicate the stock is overvalued. Investors seeking detailed valuation metrics and comprehensive analysis can access Natera's Pro Research Report, which is available through the InvestingPro platform alongside coverage for over 1,400 other US equities.
Concurrently with the insider transaction, Natera has announced significant operational advancements. The company revealed enhancements to its Panorama non-invasive prenatal test. These updates incorporate new sequencing technology designed to reduce the no-call rate to 0.5%. This technical improvement targets performance in samples characterized by low fetal fraction, thereby addressing persistent challenges in detecting chromosomal abnormalities.
Strategic expansion continues in the oncology sector as well. Natera has entered a partnership with Diakonos Oncology Corp. to facilitate a melanoma therapy trial. The collaboration utilizes Natera's Signatera test to evaluate molecular response among patients suffering from refractory melanoma. The trial protocol involves the analysis of circulating tumor DNA within patients enrolled in Diakonos' DOC-RM Phase I/II trial. This partnership underscores Natera's active role in advancing molecular diagnostics for complex cancer treatments.
Corporate governance also sees expansion with the appointment of Thomas Lynch and Eric Rubin to Natera's board of directors. Both appointees bring specialized expertise in oncology. Mr. Lynch contributes extensive experience derived from his previous roles at the Fred Hutch Cancer Center and Bristol-Myers Squibb, among other institutions. This addition reinforces the board's capability in overseeing the company's oncology-focused initiatives.
Analyst interest in Natera has also intensified with the initiation of coverage by major firms. Goldman Sachs has initiated coverage with a Neutral rating and assigned a $245 price target. The firm cites Natera's strong competitive position within the minimal residual disease market. Wolfe Research has similarly initiated coverage, assigning an outperform rating and a $260 price target. These targets are grounded in a long-term growth model for the company. These developments highlight active market scrutiny and strategic positioning as Natera advances its technological capabilities and partnerships.